Innate Pharma third quarter 2019 report
Cash, cash equivalents and financial assets of the Company amounted to €215.2 million* $79.1 million (€71.4 million**) in gross proceeds from our IPO on the Nasdaq and Global Offering Monalizumab to...
Financials and Corporate
Number of shares and voting rights of Innate Pharma as at November 1, 2019
Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “AMF”) charter, Innate...
Innate Pharma announces closing of global offering
INNATE PHARMA S.A. (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate Pharma ” or the “ Company ”), a French biotechnology company focused on discovering, developing and...
Innate Pharma announces the exercise in full of the option granted to the underwriters of its global offering and Nasdaq global select market listing to purchase 1,875,000 additional ADSs
INNATE PHARMA S.A. (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq Global Select Market: IPHA) (“ Innate ” or the “ Company ”), a French biotechnology company focused on discovering, developing and...
Innate Pharma announces the pricing of its initial public offering on the Nasdaq global select market
INNATE PHARMA S.A. (Euronext Paris: IPH – ISIN: FR0010331421) (“ Innate Pharma ” or the “ Company ”), a French biotechnology company focused on discovering, developing and commercializing first-in...
Innate Pharma announces trading halt of its ordinary shares on Euronext Paris
INNATE PHARMA S.A. (Euronext Paris: IPH – ISIN: FR0010331421) (“ Innate ” or the “ Company ”), a French biotechnology company focused on discovering, developing and commercializing first-in-class...
Innate Pharma announces launch of proposed global offering and Nasdaq listing
INNATE PHARMA S.A. (Euronext Paris: IPH – ISIN: FR0010331421) (“ Innate ” or the “ Company ”), a French biotechnology company focused on discovering, developing and commercializing first-in-class...
Monalizumab to advance to Phase III in head and neck cancer
Innate Pharma SA (the “Company” or “Innate” - Euronext Paris: FR0010331421 – IPH), today announced that AstraZeneca (LSE/STO/NYSE: AZN) will advance monalizumab into a Phase III randomized clinical...
Innate Pharma files registration statement for proposed initial public offering in the United States
INNATE PHARMA S.A. (Euronext Paris: IPH – ISIN: FR0010331421) (“ Innate ” or the “ Company ”), a French biotechnology company focused on discovering, developing and commercializing first-in-class...
Innate Pharma reports first half 2019 financial results and business update
Initiation of multi-cohort IPH4102 Phase II clinical trial (TELLOMAK) Sézary Syndrome cohort designed to be pivotal; preclinical data supports evaluating larger subsets of patients with T-cell...